RNA Cap Modification Emerges as a Switch That Governs Tumor Response to Radiotherapy

Radiotherapy remains one of the most widely deployed weapons against cancer, yet a stubborn problem has always shadowed it: many tumors simply refuse to die when the beams hit them. A new study published in the Journal of Translational Medicine points to an unexpected culprit hiding in plain sight—not in the DNA itself, and not in the proteins that repair radiation damage, but in a tiny chemical decoration on the very first nucleotide of messenger RNA. The research, led by Yuting Wu, Xi Pu, and Min Xu of Jiangsu University Cancer Institute together with colleagues at several Chinese institutions, identifies an enzyme called PCIF1 as a driver of both tumor growth and resistance to radiation, and shows that stripping away its molecular handiwork can make tumors dramatically more vulnerable to treatment.

The enzyme at the center of the story, phosphorylated CTD-interacting factor 1, or PCIF1, holds a distinction in the RNA modification field: it was the first enzyme shown to install a mark known as N6,2′-O-dimethyladenosine, abbreviated m6Am, on messenger RNA. This mark sits on the 5′ cap of mRNA, the structure that protects RNA transcripts from degradation and helps the cell’s protein-making machinery recognize them. Unlike the better-known m6A modification, which occurs internally along the RNA transcript, m6Am is confined to the cap region, where the first transcribed nucleotide carries methyl groups on both its nitrogen base and its ribose sugar. Because of this strategic position, m6Am has been implicated in controlling the stability and translation efficiency of the transcripts that carry it, though its role in cancer treatment response had remained murky.

The Jiangsu University team began by asking a deceptively simple question: what happens to PCIF1 when tumor cells are irradiated? Using RNA sequencing, they found that PCIF1 expression is elevated in tumors compared with normal tissue, but drops after radiotherapy. That inverse pattern suggested the enzyme might be doing something biologically meaningful—perhaps helping tumors survive, with radiation partially disarming it. To test this, the researchers manipulated PCIF1 levels in two well-established cancer cell lines, KPC, a pancreatic cancer model, and B16, a melanoma model, and observed the consequences both in culture dishes and in living animals.

The results were striking. When the scientists deleted PCIF1 from these cells, the cells lost much of their ability to grow in vitro, and tumors lacking the enzyme grew more slowly in mice. More importantly for clinical medicine, PCIF1 deletion sensitized the tumors to radiation. Cells without the enzyme were more likely to undergo apoptosis—the controlled self-destruction program that radiation is supposed to trigger—after being irradiated. In other words, PCIF1 appeared to be acting as a shield that tumors use to withstand the DNA-damaging assault of radiotherapy, and removing that shield restored the treatment’s killing power.

But how does an enzyme that decorates RNA caps influence something as fundamental as radiation sensitivity? To answer this, the team needed to find which RNA transcripts PCIF1 was actually marking. They deployed two complementary mapping techniques: m6Am-exo-seq, a genome-wide method that captures transcripts bearing the cap-proximal dimethylated mark, and MeRIP-PCR, which validates modification at specific targets. Both approaches converged on the same downstream target: MSH2, a gene that encodes a core component of the DNA mismatch repair system, the molecular patrol that corrects errors introduced during DNA replication and helps maintain genomic integrity.

The mechanistic chain the researchers uncovered is elegant in its logic. PCIF1 deposits m6Am marks on the MSH2 messenger RNA, and these marks promote the efficient translation of the MSH2 transcript into protein. When PCIF1 is deleted, the m6Am mark is depleted, MSH2 translation falls, and the cell’s mismatch repair capacity weakens. With MSH2 diminished, DNA damage accumulates—precisely the state a radiosensitized tumor cell finds itself in. The accumulating damage then trips one of the immune system’s most important intracellular alarms: the cGAS-STING pathway. This pathway acts as a sensor for cytoplasmic DNA, a danger signal that appears when DNA escapes the nucleus or when double-strand breaks flood the cell with fragments. Once activated, cGAS-STING signaling cascades through TANK-binding kinase 1 and interferon regulatory factor 3, ultimately stirring up antitumor immune responses.

That immune dimension turned out to be the most clinically provocative part of the study. Because cGAS-STING activation recruits and energizes immune cells, the researchers wondered whether PCIF1 deletion could amplify not just radiotherapy but also immunotherapy—specifically, the checkpoint blockade antibodies known as anti-PD-1 therapy, which unleash T cells by releasing the molecular brakes that tumors place on them. In their mouse models, combining PCIF1 deletion with radiotherapy and anti-PD-1 treatment produced enhanced antitumor efficacy compared with any single approach. Examination of the tumor microenvironment revealed why: PCIF1 deletion increased the infiltration of CD4-positive and CD8-positive T cells, the immune workhorses that directly kill tumor cells and coordinate broader immune attacks.

The study’s implications ripple across several domains of cancer biology. For the RNA modification field, it provides some of the clearest evidence yet that cap-proximal m6Am methylation is not a passive structural feature but an active regulator of cancer-relevant gene expression, with PCIF1 functioning as an oncogenic factor. For radiation oncology, it suggests that tumors may tune their radioresistance through epitranscriptomic means—adjusting the chemical decoration of their transcripts rather than mutating their DNA—and that this tunability creates a therapeutic vulnerability. For immunotherapy, it reinforces the growing recognition that the cGAS-STING axis is a critical bridge between DNA-damaging treatments and immune activation, and that interventions which push DNA damage past the repair capacity of the cell can convert a

Subject of Research: PCIF1-mediated m6Am modification of MSH2 mRNA in tumor radiosensitivity and the cGAS-STING pathway

Article Title: PCIF1-mediated depletion of N6,2’-O-dimethyladenosine in MSH2-cGAS-STING axis promote tumor radiosensitivity

Article References: Wu, Y., Pu, X., Zhang, Y., Yuan, X., Sun, X., Wang, D., Wang, X., & Xu, M. (2026). PCIF1-mediated depletion of N6,2’-O-dimethyladenosine in MSH2-cGAS-STING axis promote tumor radiosensitivity. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09020-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09020-1

Keywords: PCIF1, m6Am, radiotherapy, radiosensitivity, MSH2, cGAS-STING pathway, DNA mismatch repair, immunotherapy, anti-PD-1, epitranscriptomics, pancreatic cancer, melanoma